Our Publications
Inhibition of phosphodiesterase 4B as a novel therapeutic strategy for the treatment of refractory epilepsy.
Kinch CD, Kesler M, Dogra DD, Morin K, Ibhazehiebo K, Noschang CG, Rho JM, Kurrasch DM — 17 May 2025 (preprint)
Selective allosteric inhibition of phosphodiesterase 4B (PDE4B) as a potential anti-seizure treatment for Dravet Syndrome
Kinch, CD, et al., American Epilepsy Society 2024 Dec
A concise synthesis of biaryl PDE4D allosteric modulators
Dalby, A, et al.,Tetrahedron Lett. 2013
LINK IS NO LONGER AVAILABLE
kcna1a Mutant Zebrafish model episodic Ataxia type 1 (EA1) with epilepsy and show response to first-line therapy carbamazepine
Dogra, D., Epilepsia 2018 Mar
Metabolism-based drug discovery in zebrafish: An emerging strategy to uncover new anti-seizure therapies.
Ibhazehiebo, K, et al., 2020 May
Metabolism-based drug discovery in zebrafish: an emerging strategy to uncover new anti-seizure therapies.
Ibhazehiebo K, Rho JM, Kurrasch DM — 2020
Design and synthesis of selective phosphodiesterase 4D (PDE4D) allosteric inhibitors for the treatment of Fragile X Syndrome and other brain disorders.
Gurney, ME, et al. J Med Chem. 2019 May
A novel metabolism-based phenotypic drug discovery platform in zebrafish uncovers HDACs 1 and 3 as a potential combined anti-seizure drug target.
Ibhazehiebo K, Gavrilovici C, de la Hoz CL, Ma SC, Rehak R, Kaushik G, Meza Santoscoy PL, Scott L, Nath N, Kim DY, Rho JM, Kurrasch DM — 24 January 2018
A novel metabolism-based phenotypic drug discovery platform in zebrafish uncovers HDACs 1 and 3 as a potential combined anti-seizure drug target
Ibhazehiebo, K, et al., Brain, 2018 Mar
Discovery of triazines as selective PDE4B versus PDE4D inhibitors
Dogra, D., Epilepsia 2018 Mar
Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety
Burgin, AB, et al., Nat Biotechnol. 2010 Jan
Ibhazehiebo, K, et al. Metabolism-based drug discovery in zebrafish: An emerging strategy to uncover new anti-seizure therapies: 2020 May
View →
Gurney, ME, et al. Design and synthesis of selective phosphodiesterase 4D (PDE4D) allosteric inhibitors for the treatment of Fragile X Syndrome and other brain disorders. J Med Chem. 2019 May
View →
Ibhazehiebo, K.: A novel metabolism-based phenotypic drug discovery platform in zebrafish uncovers HDACs 1 and 3 as a potential combined anti-seizure drug target. Brain 2018 Mar
View →